What does this research mean for the field?

Trimetazidine significantly improves left ventricular ejection fraction compared to control in breast cancer patients undergoing anthracycline chemotherapy, while other agents like dexrazoxane, AA-BB, and MRAs offer specific cardioprotective benefits. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

July 7, 2025Cardio-OncologyOpen Access

Evaluating cardioprotective strategies for anthracycline-induced cardiotoxicity in breast cancer: insights from a systematic review and network meta-analysis

Q: What is the clinical evidence from this study?

Study design: Meta-Analysis. Population: Anthracycline-induced cardiotoxicity in breast cancer (n=2599). Intervention: Cardioprotective agents (trimetazidine, ACEI/ARB, beta-blockers, dexrazoxane, MRA) vs. Placebo or no treatment. Primary outcome: Left ventricular ejection fraction (LVEF) (MD 12.94, 95% CI 2.22-23.67).

View Full Paper

Ask AI

Bookmark

Key result

Trimetazidine improves LVEF by ~13% vs control in breast cancer patients on anthracycline chemotherapy.

MD 12.94
95% CI 2.22-23.67
n=2,599

Why the study?

Anthracycline-induced cardiotoxicity causes chronic cardiovascular complications and reduces long-term survival in breast cancer patients, requiring systematic evaluation of cardioprotective pharmacological agents.

Do pharmacological cardioprotective agents prevent anthracycline-induced cardiotoxicity in female breast cancer patients?

Population

2599 breast cancer patients treated with anthracyclines across 29 RCTs

Comparison

Nine classes of pharmacological agents protecting against cardiotoxicity

Design

Systematic review and Bayesian network meta-analysis of RCTs

Authors

RLRunyu LiuUniversity of Electronic Science and Technology of China CFCong FanUniversity of Electronic Science and Technology of China XLXiaoling LiuTongji University

Discussion

Member takes

Implication

Trimetazidine supports LVEF preservation during anthracycline therapy; extends meta-analytic evidence for metabolic cardioprotection in breast cancer.

Study Design

Type

Meta-Analysis (n=2,599)

Structured PICO

Do pharmacological cardioprotective agents prevent anthracycline-induced cardiotoxicity in female breast cancer patients?

Population

2,599 female breast cancer patients aged ≥ 18 years with no prior anthracycline exposure or pre-existing cardiac disease, receiving standardized anthracycline-based regimens over 4–6 cycles (12–18 weeks). Pooled from 29 RCTs.

Intervention

Nine classes of pharmacological cardioprotective agents (MRA, ACEIs/ARBs, beta-blockers, statins, dexrazoxane, antioxidants, trimetazidine, oral hypoglycemics, ivabradine) administered concurrently with or prior to anthracycline chemotherapy.

Comparator

Placebo or no additional intervention concurrently with anthracycline chemotherapy.

Outcome

Cardiac outcomes including echocardiographic parameters (LVEF, GLS, mitral E/A ratio, mitral E/e' ratio) and serological markers (BNP, cTn).surrogate

Main Result

Effect estimate: MD 12.94 (95% CI 2.22-23.67)

Trimetazidine, ACEI/ARB, beta-blockers, dexrazoxane, and MRAs show distinct, specific cardioprotective benefits against anthracycline-induced cardiotoxicity in breast cancer patients.

Limitations

Most comparisons in the analysis did not reach statistical significance
Study power limitations and variability across trials
Heterogeneity in breast cancer staging, anthracycline dosing, and treatment protocols
Low representation of certain interventions and the scarcity of direct comparisons
Language bias due to the inclusion of non-English studies
Significant heterogeneity anticipated due to differences in drug regimens, patient demographics, and outcome measurement methods
Inherent limitations in formally testing heterogeneity due to the complexity of multi-intervention comparisons

Cite This Study

Liu et al. (2025) conducted a meta-analysis in Anthracycline-induced cardiotoxicity in breast cancer (n=2,599). Cardioprotective agents (trimetazidine, ACEI/ARB, beta-blockers, dexrazoxane, MRA) vs. Placebo or no treatment was evaluated on Left ventricular ejection fraction (LVEF) (MD 12.94, 95% CI 2.22-23.67). Trimetazidine significantly improved left ventricular ejection fraction (MD 12.94) compared to control in breast cancer patients undergoing anthracycline chemotherapy.

synapsesocial.com/papers/6a178bcd5fdf2a7b88aa1f85 https://doi.org/10.1186/s40959-025-00332-7

Topics

Cardio-oncology

View Full Paper

Ask AI

Bookmark

Implication

Trimetazidine supports LVEF preservation during anthracycline therapy; extends meta-analytic evidence for metabolic cardioprotection in breast cancer.

Evaluating cardioprotective strategies for anthracycline-induced cardiotoxicity in breast cancer: insights from a systematic review and network meta-analysis

Discussion

Member takes

Implication

Study Design

Structured PICO

Main Result

Limitations

Cite This Study

Topics

Evaluating cardioprotective strategies for anthracycline-induced cardiotoxicity in breast cancer: insights from a systematic review and network meta-analysis

Discussion

Member takes

Implication

Study Design

Structured PICO

Main Result

Limitations

Cite This Study

Also Consider

Topics

Also Consider